Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20527949 | 0.89 | TSHR (0.36) | DRD3 | |
| SCHEMBL18976304 | 0.86 | HDAC1 (0.38) | DRD3 | |
| SCHEMBL20527980 | 0.84 | EPHX2 (0.31) | — | |
| SCHEMBL18975867 | 0.82 | — | — | |
| SCHEMBL21775412 | 0.79 | CA1 (0.31) | — | |
| SCHEMBL18975956 | 0.78 | JAK2 (0.31) | — | |
| SCHEMBL18975940 | 0.77 | — | — | |
| SCHEMBL18975958 | 0.77 | GRM5 (0.34) | GRM5 | |
| SCHEMBL18202836 | 0.74 | USP30 (0.33) | DRD3 | |
| SCHEMBL21341346 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567343-A | Safe and efficient method for preparing baratinib key intermediate | 瑞阳制药股份有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-114380727-A | Preparation method of 2- [1- (ethylsulfonyl) -3-azetidine ] acetonitrile | 南京焕然生物科技有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-108752254-B | Preparation method of 2- [1- (ethylsulfonyl) -3-azetidine ] acetonitrile | 道合(潍坊)医药技术有限公司 | 2021-11-02 | — | — | CN | claimed |
| US-20190100538-A1 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2019-04-04 | — | — | US | claimed |
| US-20180134713-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | LILLY CO ELI (US) | 2018-05-17 | — | — | US | claimed |
| EP-3310781-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | Eli Lilly and Company (US) | 2018-04-25 | — | — | EP | claimed |
| US-9873706-B2 | Process for the preparation of baricitinib and an intermediate thereof | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2018-01-23 | — | — | US | claimed |
| US-20170327507-A1 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-11-16 | — | — | US | claimed |
| EP-3227298-A1 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF | Sun Pharmaceutical Industries Ltd (IN) | 2017-10-11 | — | — | EP | claimed |
| WO-2016205487-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | ELI LILLY AND COMPANY (US) | 2016-12-22 | — | — | WO | claimed |
| WO-2016125080-A2 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-08-11 | — | — | WO | claimed |
| WO-2016088094-A1 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-06-09 | — | — | WO | claimed |
| CN-121800790-A | Efficient process for preparing cyclobutane derivatives | 瑞阳制药股份有限公司 | 2026-04-07 | — | — | CN | disclosed |
| EP-4713095-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Chengdu Anticancer Bioscience, Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4592286-A1 | MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR | Artivila Biopharma (CN) | 2025-07-30 | — | — | EP | disclosed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327507-A1 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF | JAK1, JAK3, BTK | DRD3 3420/4885CYP3A4 390/4885GRM5 2580/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | DRD3 1978/4885CYP3A4 2817/4885GRM5 3109/4885 |
| US-20180134713-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE | AZI2, SRMS, ABL1 | DRD3 371/4885CYP3A4 109/4885GRM5 4196/4885 |
| US-20190100538-A1 | PROCESS FOR THE PREPARATION OF BARICITINIB AND AN INTERMEDIATE THEREOF | JAK1, JAK2, JAK3 | DRD3 4252/4885CYP3A4 37/4885GRM5 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.